Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Acuta Capital Partners LLC

Acuta Capital Partners LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 53.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 9,150 shares of the biopharmaceutical company's stock after selling 10,350 shares during the quarter. Acuta Capital Partners LLC's holdings in Gilead Sciences were worth $845,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of GILD. Pine Valley Investments Ltd Liability Co acquired a new position in Gilead Sciences during the 3rd quarter worth approximately $209,000. World Investment Advisors LLC grew its holdings in Gilead Sciences by 33.6% during the third quarter. World Investment Advisors LLC now owns 25,999 shares of the biopharmaceutical company's stock worth $2,180,000 after acquiring an additional 6,535 shares during the period. Wilmington Savings Fund Society FSB raised its position in Gilead Sciences by 278.4% in the third quarter. Wilmington Savings Fund Society FSB now owns 18,660 shares of the biopharmaceutical company's stock worth $1,564,000 after acquiring an additional 13,729 shares in the last quarter. Tidal Investments LLC boosted its position in shares of Gilead Sciences by 9.9% during the 3rd quarter. Tidal Investments LLC now owns 111,464 shares of the biopharmaceutical company's stock worth $9,345,000 after purchasing an additional 10,078 shares in the last quarter. Finally, Synovus Financial Corp grew its stake in shares of Gilead Sciences by 99.6% during the 3rd quarter. Synovus Financial Corp now owns 37,265 shares of the biopharmaceutical company's stock worth $3,124,000 after purchasing an additional 18,592 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on GILD. The Goldman Sachs Group upped their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. Oppenheimer dropped their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a research report on Thursday, February 13th. Morgan Stanley increased their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Finally, Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price for the company. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $110.55.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the transaction, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at approximately $17,597,559.49. The trade was a 1.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 160,605 shares of company stock worth $16,718,136 over the last quarter. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Trading Up 0.4 %

Shares of GILD traded up $0.43 during trading hours on Friday, hitting $103.68. The stock had a trading volume of 7,032,975 shares, compared to its average volume of 7,527,490. The company's fifty day simple moving average is $108.69 and its 200 day simple moving average is $98.99. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm has a market cap of $129.10 billion, a P/E ratio of 280.22, a P/E/G ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company's revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.32) EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 3.05%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.